Related Experiment Videos
[Reversible cardiac valve abnormalities with pergolide treatment]
V Calomne1, M J-M Dupuis, T Muller
1Service de Neurologie, Clinique Saint-Pierre, Ottignies, Belgique.
Revue Neurologique
|February 24, 2004
Summary
Pergolide, a medication for Parkinson's disease, may cause heart valve damage (valvulopathy) and pulmonary hypertension. Stopping the drug resolved these cardiac symptoms in a patient, suggesting a causal link.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Pergolide is a dopamine agonist used to treat Parkinson's disease.
- Fibrotic complications, including retroperitoneal and pleural fibrosis, have been associated with pergolide use.
- Valvulopathy has not been previously reported in association with pergolide.
Observation:
- A patient with Parkinson's disease treated with pergolide developed aortic and mitral regurgitation.
- The patient also presented with pulmonary hypertension.
- Cardiac symptoms resolved after discontinuation of pergolide therapy.
Findings:
- This case report suggests a potential link between pergolide and the development of cardiac valvulopathy.
- The findings indicate that pergolide may induce or exacerbate valvular heart disease and pulmonary hypertension.
- This is one of the first reports linking pergolide to valvulopathy, following three similar cases in late 2002.
Implications:
- Clinicians should be aware of the potential cardiac risks associated with pergolide treatment.
- Monitoring for cardiac valvulopathy and pulmonary hypertension is crucial in patients receiving pergolide.
- Further research is warranted to elucidate the mechanism of pergolide-induced valvulopathy.